{ "translatorID": "186efdd2-3621-4703-aac6-3b5e286bdd86", "label": "Hindawi Publishers", "creator": "Sebastian Karcher", "target": "http://www.hindawi.com/(journals|search)/", "minVersion": "3.0", "maxVersion": "", "priority": 100, "inRepository": true, "translatorType": 4, "browserSupport": "gcsbv", "lastUpdated": "2014-05-01 00:37:52" } /* Translator Copyright (C) 2012 Sebastian Karcher an Avram Lyon This program is free software: you can redistribute it and/or modify it under the terms of the GNU Affero General Public License as published by the Free Software Foundation, either version 3 of the License, or (at your option) any later version. This program is distributed in the hope that it will be useful, but WITHOUT ANY WARRANTY; without even the implied warranty of MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE. See the GNU Affero General Public License for more details. You should have received a copy of the GNU Affero General Public License along with this program. If not, see . */ function detectWeb(doc,url) { var namespace = {"x" : "http://www.w3.org/1999/xhtml"} var xpath='//x:meta[@name="citation_journal_title"]'; if (ZU.xpath(doc, xpath, namespace).length > 0) { return "journalArticle"; } if (url.indexOf("/search/")!=-1 || url.indexOf("/journals/")!=-1) { multxpath = '//x:div[@class="middle_content"]/x:ul/x:li/x:a[contains(@href, "/journals/")]|\ //x:div[contains(@id, "SearchResult")]/x:ul/x:li/x:a[contains(@href, "/journals/")]' if (ZU.xpath(doc, multxpath, namespace).length>0){ return "multiple"; } } return false; } function doWeb(doc,url) { if (detectWeb(doc, url) == "multiple") { var namespace = {"x" : "http://www.w3.org/1999/xhtml"} var hits = {}; var urls = []; resultxpath = '//x:div[@class="middle_content"]/x:ul/x:li/x:a[contains(@href, "/journals/")]|\ //x:div[contains(@id, "SearchResult")]/x:ul/x:li/x:a[contains(@href, "/journals/")]' var results = ZU.xpath(doc, resultxpath, namespace); for (var i in results) { hits[results[i].href] = results[i].textContent; } Z.selectItems(hits, function(items) { if (items == null) return true; for (var j in items) { urls.push(j); } ZU.processDocuments(urls, doWeb); }); } else { var translator = Zotero.loadTranslator('web'); //use Embedded Metadata translator.setTranslator("951c027d-74ac-47d4-a107-9c3069ab7b48"); translator.setDocument(doc); translator.setHandler('itemDone', function(obj, item) { if(!item.pages && item.DOI) { // use article ID as a page (seems to be the last part of URL/DOI) item.pages = 'e' + item.DOI.substr(item.DOI.lastIndexOf('/') + 1); } item.extra = ""; item.complete(); }); translator.translate(); } } /** BEGIN TEST CASES **/ var testCases = [ { "type": "web", "url": "http://www.hindawi.com/journals/jo/2012/", "items": "multiple" }, { "type": "web", "url": "http://www.hindawi.com/journals/scientifica/2012/942507/", "items": [ { "itemType": "journalArticle", "creators": [ { "firstName": "C. Francisco", "lastName": "Espinel", "creatorType": "author" }, { "firstName": "Shaughn", "lastName": "Keating", "creatorType": "author" }, { "firstName": "Hanina", "lastName": "Hibshoosh", "creatorType": "author" }, { "firstName": "Bret", "lastName": "Taback", "creatorType": "author" }, { "firstName": "Kathie-Ann", "lastName": "Joseph", "creatorType": "author" }, { "firstName": "Mahmoud", "lastName": "El-Tamer", "creatorType": "author" }, { "firstName": "Sheldon", "lastName": "Feldman", "creatorType": "author" } ], "notes": [], "tags": [], "seeAlso": [], "attachments": [ { "title": "Full Text PDF", "mimeType": "application/pdf" }, { "title": "Snapshot" } ], "language": "en", "abstractNote": "Background. The MammaPrint (MP) diagnostic assay stratifies breast cancer patients into high- and low-risk groups using mRNA analysis of a 70-gene profile. The assay is validated for assessment of patients with estrogen receptor positive or negative tumors less than 5 cm with 3 or fewer malignant lymph nodes. TargetPrint (TP) is an assay for assessing estrogen, progesterone, and HER2-neu receptor status based on mRNA expression. A potential limitation of these assays is that they require an evaluation of fresh tissue samples. There is limited published experience describing MP or TP implementation. Methods. Over 10 months, 4 breast surgeons obtained samples from 54 patients for MP/TP analysis. The samples were analyzed by Agendia Labs. The tumors were independently evaluated for receptor status using immunohistochemistry (IHC). Retrospectively, we identified patients who were assessed by MP/TP during this period. Patients who underwent OncotypeDx evaluation were also identified. Results. Of the 54 patients receiving MP, 4 were found ineligible for MP risk assessment because >3 lymph nodes were found to be malignant. Out of all eligible patients, 14/50 (28%) had samples whose quantity of tumor was not sufficient for analysis (QNS). Out of eligible patients with tumors <1 cm, 7/8 (88%) had QNS samples. 7/42 with tumors ≥1 cm (17%) had QNS samples. Nine patients had discordant receptor results when evaluated by IHC versus. TP. Of patients who also underwent OncotypeDx testing, 6/14 (43%) had discordant results with MP. Conclusions. This study indicates that using MP/TP assay is feasible in a tertiary care center but there may be utility in limiting MP testing to patients with tumors between 1 and 5 cm due to high likelihood of uninformative results in subcentimeter tumors. Further study is needed to explore the discordance between oncotype and MP results.", "DOI": "10.6064/2012/942507", "url": "http://www.hindawi.com/journals/scientifica/2012/942507/abs/", "libraryCatalog": "www.hindawi.com", "shortTitle": "MammaPrint Feasibility in a Large Tertiary Urban Medical Center", "title": "MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience", "publicationTitle": "Scientifica", "volume": "2012", "date": "2012/12/31", "pages": "e942507" } ] }, { "type": "web", "url": "http://www.hindawi.com/search/all/data/", "items": "multiple" } ] /** END TEST CASES **/